Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics’ revenue came in below expectations in the second fiscal quarter of 2026, with revenue of $37.7 million trailing the $42.2 million estimate (-10.7%) and edging up 1.3% from about $37.2 million a year ago; results were reported August 10, 2026. The quarter was anchored by the company’s oncology supportive care portfolio, including SUSTOL and CINVANTI, as gross profit of roughly $26.1 million translated to a gross margin of about 69% on the slightly higher sales base. Operating results remained slightly negative, with an operating loss of roughly $2.0 million and an operating margin of about -5%, while net loss widened to about $5.5 million versus roughly $2.4 million a year ago. EPS was -$0.03, down from -$0.02 in the prior-year period. Cash flow was also negative, with negative operating cash flow of roughly $2.2 million, and the company repurchased about $0.1 million of stock. For the next period, consensus calls for EPS of -$0.03 on revenue of $37.5 million.